Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite , is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC 50 of 40 μM In Vitro T-βMCA sodium inhibits FXR reporter activity in the CRC cell line HT29 (EC 50 ~10 μM). T-βMCA sodium dose-dependently increases WNT signaling in HT29 and HCT116 cells. T-βMCA sodium induces proliferation and DNA damage in Lgr5 + cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo T-βMCA sodium (400 mg/kg; i.g.; twice a week; for 6 weeks) can effectively recapitulate the ability of HFD to promote CRC progression. T-βMCA sodium treatment also significantly increases levels of serum cytokines, including IFN-γ, IL-6, and IL-17. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: APCmin/+ miceDosage: 400 mg/kg Administration: Oral gavage; twice a week; for 6 weeks Result: Markedly decreased intestinal integrity and accelerated tumor growth in the intestine and colon. Form:Solid IC50& Target:IC50: 40 μM (FXR)